CRISPR Therapeutics AG

Name: CRISPR Therapeutics AG standardized financial statements, quarterly
Creator: Listed

CRSPNasdaqCIK 1674416HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$10.2m, Q2 FY2026

Operating income−$117.3m, Q2 FY2026

Net income−$91.2m, Q2 FY2026

CRISPR Therapeutics AG, income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	0.0	201	0.5	0.5	0.6	35.7	0.9	0.9	0.9	0.9	1.5	10.2
Research and development	$m	90.7	95.1	76.2	80.2	82.2	71.7	72.5	69.9	58.9	83.5	68.6	67.2
Operating income	$m	(132)	69.6	(141)	(151)	(110)	(64.6)	(148)	(229)	(132)	(155)	(130)	(117)
Income tax	$m	0.4	0.2	0.7	1.3	0.9	0.7	1.1	1.3	0.6	0.6	0.8	1.0
Net income	$m	(112)	89.3	(117)	(126)	(85.9)	(37.3)	(136)	(209)	(106)	(131)	(123)	(91.2)
Diluted EPS	$ per share	(1.41)	not reported	(1.43)	(1.49)	(1.01)	not reported	(1.58)	(2.40)	(1.17)	not reported	(1.28)	(0.94)
Basic EPS	$ per share	(1.41)	not reported	(1.43)	(1.49)	(1.01)	not reported	(1.58)	(2.40)	(1.17)	not reported	(1.28)	(0.94)

Balance sheet

Cash and equivalents$291.3m, Q2 FY2026

Long-term debt$586.2m, Q2 FY2026

Shareholders' equity$1.75bn, Q2 FY2026

CRISPR Therapeutics AG, balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	528	389	707	484	226	298	235	194	286	348	423	291
Current assets	$m	1,761	1,908	2,120	2,010	1,944	1,937	1,868	1,734	1,929	1,986	2,448	2,372
Total assets	$m	2,087	2,230	2,439	2,340	2,256	2,242	2,166	2,030	2,245	2,265	2,726	2,651
Current liabilities	$m	111	109	119	128	89.8	87.8	119	104	119	149	136	133
Total liabilities	$m	359	347	355	359	316	310	337	319	329	343	911	904
Long-term debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	0.0	585	586
Shareholders' equity	$m	1,728	1,883	2,084	1,981	1,940	1,932	1,829	1,711	1,916	1,922	1,815	1,747

Cash flow

Operating cash flow−$83.5m, Q2 FY2026

Capital expenditure$648.0k, Q2 FY2026

CRISPR Therapeutics AG, cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(39.9)	(96.1)	110	(95.6)	(107)	(50.0)	(53.9)	(114)	(84.6)	(92.6)	(109)	(83.5)
Capital expenditure	$m	2.1	0.7	0.7	0.7	0.2	0.3	0.2	0.1	0.1	0.5	0.5	0.6
Share repurchases	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)96.51m, Q2 FY2026

CRISPR Therapeutics AG, shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	78.0	78.7	79.1	79.4	81.8	84.9	85.2	85.9	87.1	91.3	96.1	96.5

Shares outstanding: 96.69m at Jul 31, 2026, from the cover of the 10-Q filed Aug 3, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. Listed shows no prices and gives no investment advice.